TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porterโs Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Dyspepsia Market, by Diagnosis
6.1 Introduction
6.2 Blood Tests
6.3 Breath Tests
6.4 Stool Tests
6.5 Endoscopy
6.6 X-ray
6.7 CT scan
6.8 Others
Chapter 7. Global Dyspepsia Market, by Treatment
7.1 Introduction
7.2 Antacids
7.2.1 Calcium Carbonate
7.2.2 Loperamide
7.2.3 Simethicone
7.2.4 Sodium Bicarbonate
7.2.5 Others
7.3 Antibiotics
7.3.1 Amoxicillin
7.3.2 Clarithromycin
7.3.3 Metronidazole
7.3.4 Others
7.4 H2 Blockers
7.4.1 Cimetidine
7.4.2 Famotidine
7.4.3 Nizatidine
7.4.4 Ranitidine
7.4.5 Others
7.5 Proton Pump Inhibitors (PPIs)
7.5.1 Esomeprazole
7.5.2 Lansoprazole
7.5.3 Omeprazole
7.6 Prokinetics
7.6.1 Bethanechol
7.6.2 Metoclopramide
7.7 Psychological Therapies
7.8 Others
Chapter 8. Global Dyspepsia Market, by End-User
8.1 Introduction
8.2 Hospitals and Clinics
8.3 Ambulatory Surgical Centers
8.4 Pharmacies
8.5 Diagnostic Centers
8.6 Others
Chapter 9. Global Dyspepsia Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 AstraZeneca
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials
11.2.4 Key Developments
11.1.5 SWOT Analysis
11.2 GlaxoSmithKline
11.2.1 Company Overview
11.2.2 Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Takeda Pharmaceutical Company
11.3.1 Company Overview
11.3.2 Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Johnson & Johnson
11.4.1 Company Overview
11.4.2 Type/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Eisai Co., Ltd
11.5.1 Company Overview
11.5.2 Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Abbott Laboratories
11.6.1 Company Overview
11.6.2 Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 SALIX PHARMACEUTICALS
11.7.1 Overview
11.7.2 Type Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Bayer AG
11.8.1 Overview
11.8.2 Type Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Boehringer Ingelheim GmbH
11.9.1 Overview
11.9.2 Type Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Sanofi
11.10.1 Overview
11.10.2 Type Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Allergan Plc
11.11.1 Overview
11.11.2 Type Overview
11.11.3 Financials
11.11.4 Key Developments
Chapter 12 Appendix
LIST OF TABLES
Table 1 Dyspepsia Market Industry Synopsis, 2020โ2027
Table 2 Global Dyspepsia Market Estimates & Forecast, 2020โ2027, (USD Million)
Table 3 Global Dyspepsia Market, by Region, 2020โ2027, (USD Million)
Table 4 Global Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 5 Global Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table6 Global Dyspepsia Market, by End-User, 2020โ2027, (USD Million
Table7 North America: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 8 North America: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 9 North America: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 10 US: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 11 US: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 12 US: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 13 Canada: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 14 Canada: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 15 Canada: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 16 South America: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 17 South America: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 18 South America: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 19 Europe: Dyspepsia Market, Diagnosis, 2020โ2027, (USD Million)
Table 20 Europe: Dyspepsia Market, Type, 2020โ2027, (USD Million)
Table 21 Europe: Dyspepsia Market, Technology, 2020โ2027, (USD Million)
Table 32 Europe: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 23 Europe: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 24 Western Europe: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 25 Western Europe: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 26 Western Europe: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 27 Eastern Europe: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 28 Eastern Europe: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 29 Eastern Europe: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 30 Asia-Pacific: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 31 Asia-Pacific: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 32 Asia-Pacific: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
Table 33 Middle East & Africa: Dyspepsia Market, by Diagnosis, 2020โ2027, (USD Million)
Table 34 Middle East & Africa: Dyspepsia Market, by Treatment, 2020โ2027, (USD Million)
Table 35 Middle East & Africa: Dyspepsia Market, by End-User, 2020โ2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Dyspepsia Market
Figure 3 Market Dynamics for Global Dyspepsia Market
Figure 4 Global Dyspepsia Market Share, by Diagnosis 2020
Figure 5 Global Dyspepsia Market Share, by Treatment 2020
Figure 6 Global Dyspepsia Market Share, by End-User, 2020
Figure 7 Global Dyspepsia Market Share, by Region, 2020
Figure 8 North America Dyspepsia Market Share, by Country, 2020
Figure 9 Europe Dyspepsia Market Share, by Country, 2020
Figure 10 Asia-Pacific Dyspepsia Market Share, by Country, 2020
Figure 11 Middle East & Africa Dyspepsia Market Share, by Country, 2020
Figure 12 Global Dyspepsia Market: Company Share Analysis, 2020 (%)
Figure 13 AstraZeneca: Key Financials
Figure 14 AstraZeneca: Segmental Revenue
Figure 15 AstraZeneca: Geographical Revenue
Figure 16 GlaxoSmithKline: Key Financials
Figure 17 GlaxoSmithKline: Segmental Revenue
Figure 18 GlaxoSmithKline: Geographical Revenue
Figure 19 Takeda Pharmaceutical Company : Key Financials
Figure 20 Takeda Pharmaceutical Company : Segmental Revenue
Figure 21 Takeda Pharmaceutical Company : Geographical Revenue
Figure 22 Johnson & Johnson : Key Financials
Figure 23 Johnson & Johnson : Segmental Revenue
Figure 24 Johnson & Johnson : Geographical Revenue
Figure 25 Abbott Laboratories : Key Financials
Figure 26 Abbott Laboratories : Segmental Revenue
Figure 27 Abbott Laboratories : Geographical Revenue
Figure 28 Eisai Co., Ltd : Key Financials
Figure 29 Eisai Co., Ltd : Segmental Revenue
Figure 30 Eisai Co., Ltd : Geographical Revenue
Figure 31 SALIX PHARMACEUTICALS : Key Financials
Figure 32 SALIX PHARMACEUTICALS : Segmental Revenue
Figure 33 SALIX PHARMACEUTICALS : Geographical Revenue
Figure 34 Bayer AG: Key Financials
Figure 35 Bayer AG: Segmental Revenue
Figure 36 Bayer AG: Geographical Revenue
Figure 37 Boehringer Ingelheim GmbH : Key Financials
Figure 38 Boehringer Ingelheim GmbH : Segmental Revenue
Figure 39 Boehringer Ingelheim GmbH : Geographical Revenue
Figure 40 Sanofi: Key Financials
Figure 41 Sanofi: Segmental Revenue
Figure 42 Sanofi: Geographical Revenue
Figure 43 Allergan Plc: Key Financials
Figure 44 Allergan Plc: Segmental Revenue
Figure 45 Allergan Plc: Geographical Revenue